Company: DMAC
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001437749-25-034469
Chunk: 5

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part II, Item 1A
Chunk 5
---
 research to understand new technologies or establish new standards, is subject to the political process, which is inherently fluid and unpredictable. Such government agencies also have been subject to reductions in funding and downsizing of agency staffing levels, which could materially impact our business and operations. The current U. S. Presidential administration has implemented or proposed policies that may affect the FDA review process, including efforts to downsize the federal workforce, remove job elimination protections for federal workers, limit certain communications, and potentially impact user fee reauthorization. If political pressure, global health concerns, or other factors prevent the FDA or other regulatory authorities from conducting their regular reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications

During the quarterly period ended September 30, 2025, noneof our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “ Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408, respectively, of SEC Regulation S-K.

22

ITEM 6. EXHIBITS

The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:

  Exhibit      Description                                                                                                                                                                                               Manner of Filing                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                          
      No.                                                                                                                                                                                                                                                                                                                                                                                 
      3.1      Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025                                                                                                                                      Incorporated by reference to Exhibit 3.1 to DiaMedica’s Quarterly Report on Form 10-Q for the period ended June 30, 2025                                         
      3.2      Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023                                                                                                                       Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and